{
    "body": "Which molecule is targeted by Daratumumab?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25964097", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25764134", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25531698", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26137203", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25626316", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21109694", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24555809", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24053207", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21187443", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25988285", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24849305", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25865943"
    ], 
    "ideal_answer": [
        "Daratumumab, an investigated anti-cancer drug targeting CD38, has been of great interest in the treatment of CD38-expressing malignancies, especially multiple myeloma.", 
        "Daratumumab is a novel, high-affinity, therapeutic human monoclonal antibody against unique CD38 epitope with broad-spectrum killing activity."
    ], 
    "exact_answer": [
        "CD38"
    ], 
    "type": "factoid", 
    "id": "56c04412ef6e39474100001b", 
    "snippets": [
        {
            "offsetInBeginSection": 189, 
            "offsetInEndSection": 357, 
            "text": "Daratumumab, an investigated anti-cancer drug targeting CD38, has been of great interest in the treatment of CD38-expressing malignancies, especially multiple myeloma. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25865943", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 347, 
            "offsetInEndSection": 489, 
            "text": "Daratumumab is a novel, high-affinity, therapeutic human monoclonal antibody against unique CD38 epitope with broad-spectrum killing activity.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137203", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 775, 
            "offsetInEndSection": 937, 
            "text": "This review focuses on the CD38 antigen and its targeting with daratumumab and provides an update on the results of recent clinical studies involving daratumumab.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137203", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 151, 
            "text": "BACKGROUND: Daratumumab (DARA), a promising novel therapy for multiple myeloma, is an IgG1\u03ba monoclonal antibody that recognizes CD38 on myeloma cells. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764134", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1379, 
            "offsetInEndSection": 1462, 
            "text": "CONCLUSION: DARA causes panreactivity in vitro by binding to CD38 on reagent RBCs. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764134", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 279, 
            "offsetInEndSection": 496, 
            "text": "Here, we describe that treatment of multiple myeloma patients with daratumumab, a novel anti-CD38 MoAb, resulted in false-positive indirect antiglobulin tests (IATs) for all patients for 2 to 6 months after infusion. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25988285", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 702, 
            "offsetInEndSection": 842, 
            "text": "Interference of daratumumab and three other anti-CD38 MoAbs was studied using fresh-frozen plasma spiked with different MoAb concentrations.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25988285", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 189, 
            "offsetInEndSection": 356, 
            "text": "Daratumumab, an investigated anti-cancer drug targeting CD38, has been of great interest in the treatment of CD38-expressing malignancies, especially multiple myeloma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25865943", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 347, 
            "offsetInEndSection": 490, 
            "text": "Daratumumab is a novel, high-affinity, therapeutic human monoclonal antibody against unique CD38 epitope with broad-spectrum killing activity. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137203", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 262, 
            "offsetInEndSection": 444, 
            "text": "This article focuses on the basic and clinical aspects of several emerging and promising novel MoAbs for MM, such as elotuzumab which targets CS1 and daratumumab which targets CD38. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25626316", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 288, 
            "offsetInEndSection": 569, 
            "text": "This is likely to change within the next few years with a number of mAb therapies being assessed in late stage clinical trials, most notably, the anti-CS-1 mAb, elotuzumab, and the anti-CD38 mAb, daratumumab, which are currently being evaluated in Phase III clinical trials for MM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25964097", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 509, 
            "offsetInEndSection": 651, 
            "text": "Over the last 2 years, an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patients with MM", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24555809", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 88, 
            "offsetInEndSection": 230, 
            "text": "Over the last 2 years, an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patients with MM", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25531698", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 132, 
            "text": "Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 182, 
            "offsetInEndSection": 538, 
            "text": "In this study, we describe the cytotoxic mechanisms of action of daratumumab, a novel, high-affinity, therapeutic human mAb against a unique CD38 epitope. Daratumumab induced potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines as well as in patient MM cells, both with autologous and allogeneic effector cells. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 538, 
            "offsetInEndSection": 1047, 
            "text": "Daratumumab stood out from other CD38 mAbs in its strong ability to induce complement-dependent cytotoxicity in patient MM cells. Importantly, daratumumab-induced Ab-dependent cellular cytotoxicity and complement-dependent cytotoxicity were not affected by the presence of bone marrow stromal cells, indicating that daratumumab can effectively kill MM tumor cells in a tumor-preserving bone marrow microenvironment. In vivo, daratumumab was highly active and interrupted xenograft tumor growth at low dosing. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 776, 
            "offsetInEndSection": 938, 
            "text": "This review focuses on the CD38 antigen and its targeting with daratumumab and provides an update on the results of recent clinical studies involving daratumumab.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137203", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 614, 
            "offsetInEndSection": 678, 
            "text": "elotuzumab which targets CS1 and daratumumab which targets CD38.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24053207", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 372, 
            "offsetInEndSection": 444, 
            "text": "such as elotuzumab which targets CS1 and daratumumab which targets CD38.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25626316", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1821, 
            "offsetInEndSection": 2034, 
            "text": "Novel therapy strategies include targeted and stroma-directed approaches. Antibodies targeting CS-1 (elotuzumab) and CD38 (daratumumab) in particular are currently undergoing advanced clinical phase II/III trials.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849305", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 533, 
            "offsetInEndSection": 653, 
            "text": "an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patients with MM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24555809", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 674, 
            "offsetInEndSection": 842, 
            "text": "This review focuses on the basic and clinical aspects of two emerging and promising novel MoAbs for MM, elotuzumab which targets CS1 and daratumumab which targets CD38.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24053207", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2014, 
            "offsetInEndSection": 2153, 
            "text": "Antibodies targeting CS-1 (elotuzumab) and CD38 (daratumumab) in particular are currently undergoing advanced clinical phase II/III trials.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849305", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 230, 
            "offsetInEndSection": 373, 
            "text": "Over the last 2 years, an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patients with MM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25531698", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 650, 
            "offsetInEndSection": 793, 
            "text": "Over the last 2 years, an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patients with MM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24555809", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1317, 
            "offsetInEndSection": 1421, 
            "text": "These findings support clinical development of daratumumab for the treatment of CD38-positive MM tumors.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 165, 
            "text": "Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21109694", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1888, 
            "offsetInEndSection": 2027, 
            "text": "Antibodies targeting CS-1 (elotuzumab) and CD38 (daratumumab) in particular are currently undergoing advanced clinical phase II/III trials.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849305", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 182, 
            "offsetInEndSection": 337, 
            "text": "In this study, we describe the cytotoxic mechanisms of action of daratumumab, a novel, high-affinity, therapeutic human mAb against a unique CD38 epitope. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 200, 
            "offsetInEndSection": 737, 
            "text": "Daratumumab is a novel human CD38 monoclonal antibody which kills CD38+ multiple myeloma cells via antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and apoptosis. DESIGN AND METHODS: To explore the effect of lenalidomide combined with daratumumab, we first carried out standard antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity assays in which the CD38+ multiple myeloma cell line UM-9 and primary multiple myeloma cells isolated from patients were used as target cells. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21109694", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1220, 
            "offsetInEndSection": 1324, 
            "text": "These findings support clinical development of daratumumab for the treatment of CD38-positive MM tumors.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 182, 
            "offsetInEndSection": 336, 
            "text": "In this study, we describe the cytotoxic mechanisms of action of daratumumab, a novel, high-affinity, therapeutic human mAb against a unique CD38 epitope.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 266, 
            "offsetInEndSection": 653, 
            "text": "A novel therapeutic strategy that effectively targets specific molecules on myeloma cells and also potentially overcomes tumor microenvironment-mediated drug resistance and the downstream effects of genetic instability is thus urgently needed. Over the last 2 years, an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patients with MM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24555809", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 776, 
            "offsetInEndSection": 941, 
            "text": "This review focuses on the CD38 antigen and its targeting with daratumumab and provides an update on the results of recent clinical studies involving daratumumab.  .", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137203", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 112, 
            "offsetInEndSection": 232, 
            "text": "an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patients with MM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25531698", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 510, 
            "offsetInEndSection": 678, 
            "text": "This review focuses on the basic and clinical aspects of two emerging and promising novel MoAbs for MM, elotuzumab which targets CS1 and daratumumab which targets CD38.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24053207", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 510, 
            "offsetInEndSection": 653, 
            "text": "Over the last 2 years, an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patients with MM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24555809", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 89, 
            "offsetInEndSection": 232, 
            "text": "Over the last 2 years, an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patients with MM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25531698", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 263, 
            "offsetInEndSection": 444, 
            "text": "This article focuses on the basic and clinical aspects of several emerging and promising novel MoAbs for MM, such as elotuzumab which targets CS1 and daratumumab which targets CD38.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25626316", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1895, 
            "offsetInEndSection": 2034, 
            "text": "Antibodies targeting CS-1 (elotuzumab) and CD38 (daratumumab) in particular are currently undergoing advanced clinical phase II/III trials.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849305", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 190, 
            "offsetInEndSection": 357, 
            "text": "Daratumumab, an investigated anti-cancer drug targeting CD38, has been of great interest in the treatment of CD38-expressing malignancies, especially multiple myeloma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25865943", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 352, 
            "offsetInEndSection": 599, 
            "text": "We hypothesized that the observed panreactivity reflected DARA binding to CD38 on reagent RBCs, and we investigated methods to prevent this binding.STUDY DESIGN AND METHODS: DARA binding to CD38+ or CD38- HL60 cells was assessed by flow cytometry.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764134", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1086, 
            "offsetInEndSection": 1279, 
            "text": "Flow cytometry experiments confirmed DARA binding to CD38+ HL60 cells, but not to CD38- controls. DTT treatment of CD38+ HL60 cells reduced DARA binding by 92% by denaturing cell surface CD38. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25764134", 
            "endSection": "abstract"
        }
    ]
}